Product Program year 2024 Source: CMS Open Payments

Topiramate

Drug Neurology

NDC 0832-1071-30

Open in the dashboard

General payments

$2,746

167 payments

Research payments

$364,028

121 payments

Through program year 2024, $2,746 in general payments and $364,028 in research payments were reported against Topiramate (Neurology).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

5 rows
Year Kind Amount Payments
2024 Research $1,320 1
2023 Research $106,121 40
2022 Research $99,741 42
2021 General $2,746 167
2021 Research $156,847 38

Breakdown

Who paid General payments · program year 2021
  1. Upsher-Smith Laboratories LLC $2,746 167 payments
Top recipients General payments · program year 2021
  1. Arturo Sanchez Physician Assistant · Phoenix, AZ $142 5% · 11 payments
  2. Nirmala Aryal Neurology · Phoenix, AZ $128 5% · 8 payments
  3. Maninder Kahlon Neurology · Sun City, AZ $121 4% · 9 payments
  4. Ikedieze Chukwu Internal Medicine · El Paso, TX $97 4% · 6 payments
  5. Ralph Pagano Neurology · Phoenix, AZ $94 3% · 9 payments

The top 5 of 69 recipients; each share is of general payments naming this product in 2021.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2021
  1. Neurology Psychiatry & Neurology $1,252 46% · 27 practitioners
  2. Nurse Practitioner, Family Nurse Practitioner $459 17% · 14 practitioners
  3. Physician Assistant $386 14% · 8 practitioners
  4. Internal Medicine $181 7% · 4 practitioners
  5. Family Medicine $127 5% · 5 practitioners

The top 5 of 15 specialties; each share is of general payments naming this product to practitioners with a specialty in 2021. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2021
  1. Arizona $1,669 61% · 37 recipients
  2. New Mexico $447 16% · 12 recipients
  3. Texas $350 13% · 6 recipients
  4. Florida $151 6% · 7 recipients
  5. Massachusetts $59 2% · 3 recipients

The top 5 of 7 states; each share is of general payments naming this product in 2021 where a state was reported.

The top 25 states, free in the app

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

2,709,469

Prescriptions dispensed, refills included

Drug cost

$71,683,813

Paid at the pharmacy, in all

Medicare Part D drugs matched to TOPIRAMATE, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Topiramate Same name 78,982 2,675,486 $32,767,098
Topamax Topiramate Same name 658 11,657 $18,525,659
Topiramate Er Topiramate Same name 924 16,398 $11,925,818
Trokendi Xr Topiramate Same name 292 5,049 $7,654,264
Qudexy Xr Topiramate Same name 22 300 $450,720
Eprontia Topiramate Same name 41 579 $360,254

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 428 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Gregory Connor Neurology OK 1,461 $18,784 None on record
Casilda Balmaceda Neurology NY 1,013 $14,334 None on record
Shephali Patel Psychiatry IL 969 $7,898 None on record
Francisco Parra Psychiatry PR 934 $4,310 None on record
James Valeriano Neurology PA 898 $158,588 None on record

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See more in the dashboard: 25 with a free account, all 428 with Patron
167 general · 121 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record